3,4-(methylenedioxy)-6-nitrophenylethane | 433289-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3,4-(methylenedioxy)-6-nitrophenylethane
• 英文别名: ethyl-6-nitro-benzo[1,3]dioxane；5-Ethyl-6-nitro-1,3-benzodioxole
• CAS: 433289-07-7
• 化学式: C₉H₉NO₄
• 分子量: 195.175
• InChiKey: DEFWQCMOUFADFO-UHFFFAOYSA-N

物化性质

• 沸点：
  291.5±29.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  64.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,4-(methylenedioxy)-6-nitrophenylethane 在 苄基三甲基氢氧化铵 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 甲苯 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Light-directed maskless synthesis of peptide arrays using photolabile amino acid monomers

  摘要：

  已经开发出用于光刻固相肽合成的新型光不稳定氨基酸单体，并且描述了使用新的构建模块无掩模合成可单独寻址的肽微阵列的方法；这些肽微阵列适用于重复表位结合测定。

  DOI：

  10.1039/b601390b
• 作为产物：
  描述：

  3,4-亚甲二氧苯乙酮 在 氢氧化钾 、 硝酸 、 一水合肼 作用下， 以 二氯甲烷 、 乙二醇 为溶剂， 反应 3.0h， 生成 3,4-(methylenedioxy)-6-nitrophenylethane
  参考文献：
  名称：

  Light-directed maskless synthesis of peptide arrays using photolabile amino acid monomers

  摘要：

  已经开发出用于光刻固相肽合成的新型光不稳定氨基酸单体，并且描述了使用新的构建模块无掩模合成可单独寻址的肽微阵列的方法；这些肽微阵列适用于重复表位结合测定。

  DOI：

  10.1039/b601390b

文献信息

• Bi-functionalised metallocenes use for marking biological molecules
  申请人：Chaix-Bauvais Carole

  公开号：US20050038234A1

  公开（公告）日：2005-02-17

  The invention relates to bi-functionalised metallocenes of general formula (I) where Me=a transition metal, preferably chosen from Fe, Ru and Os, Y and Z, when identical are selected from —(CH 2 ) n —O—, (CH 2 )—O—[(CH 2 ) 2 —O] P — and —(CH 2 ) q —CONH—(CH 2 ) r —O—, or Y=—(CH 2 ) S —NH— and Z=—(CH 2 ) t —COO—, n =a whole number from 3 to 6 inclusive, p=a whole number from 1 to 4 inclusive, q=a whole number from 0 to 2 inclusive, r=a whole number from 0 to 2 inclusive, s=a whole number from 2 to 5 inclusive, t=a whole number from 3 to 6 inclusive, R and R′=H atoms or are protective groups used in oligonucleotide and peptide synthesis, where at least one of R or R′ is protective group used in oligonucleotide and peptide synthesis and R and R′ are as defined below: (i) when Z and Y are selected from (CH 2 ) n —O—, —(CH 2 )—O—[(CH 2 ) 2 —O] p — and —(CH 2 ) q —CONH—(CH 2 ) r —O—, then R and R′ are protective groups used in oligonucleotide synthesis and R is a group which can leave a free OH group after deprotection, preferably a photolabile group such as monomethroxythoxytrityl, dimethoxytrityl, t-butyldimethylsilyl, acetyl or trifluroacetyl, and R′ is a phosphorylated group which can react with a free OH, preferably a phosphodiester, phosphoramidite or H-phosphonate and (ii) when Y=—(CH 2 ) n —NH— and Z=—(CH 2 ) t —COO—, then R is a protective group used in the synthesis of peptides and is an amino-protecting group, preferably 9-fluorenyloxycarbonyl, t-butoxycarbonyl or benzyloxycarbonyl and R′=H. The above is applied in marking.

  本发明涉及一种双功能化金属茂，其通式为(I)，其中Me为过渡金属，优选为Fe、Ru或Os，Y和Z相同时选自—(CH2)n—O—、(CH2)—O—[(CH2)2—O]p—和—(CH2)q—CONH—(CH2)r—O—，或者Y=—(CH2)s—NH—且Z=—(CH2)t—COO—，其中n为3至6的整数，p为1至4的整数，q为0至2的整数，r为0至2的整数，s为2至5的整数，t为3至6的整数，R和R′为H原子或寡核苷酸和肽合成中使用的保护基团，其中至少一个R或R′为寡核苷酸和肽合成中使用的保护基团，且R和R′定义如下：(i) 当Z和Y选自(CH2)n—O—、—(CH2)—O—[(CH2)2—O]p—和—(CH2)q—CONH—(CH2)r—O—时，R和R′为寡核苷酸合成中使用的保护基团，R为脱保护后可留下自由OH基团的基团，优选为光敏基团，如单甲氧基三苯甲基、二甲氧基三苯甲基、叔丁基二甲基硅烷、乙酰基或三氟乙酰基，R′为可与自由OH反应的磷酸化基团，优选为磷酸二酯、磷酸酰胺或H-膦酸酯；(ii) 当Y=—(CH2)n—NH—且Z=—(CH2)t—COO—时，R为肽合成中使用的保护基团，为氨基保护基团，优选为9-芴基氧羰基、叔丁氧羰基或苄氧羰基，R′=H。上述应用于标记。
• Wilkinson's Catalyst Catalyzed Selective Hydrogenation of Olefin in the Presence of an Aromatic Nitro Function:  A Remarkable Solvent Effect
  作者：Angélique Jourdant、Eduardo González-Zamora、Jieping Zhu

  DOI：10.1021/jo025595q

  日期：2002.5.1

  Optimal conditions for chlorotris(triphenylphosphine)rhodium(I) (Wilkinson's catalyst) catalyzed selective saturation of a double bond in the presence of a nitro function are developed. Aryl iodide and benzyl ether are also tolerated under these hydrogenation conditions.

  提出了在硝基官能团存在的条件下，氯三（三苯基膦）铑（I）（Wilkinson催化剂）催化双键选择性饱和的最佳条件。在这些氢化条件下也可以接受芳基碘化物和苄基醚。
• Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof
  申请人：Paris Daniel

  公开号：US20080058330A1

  公开（公告）日：2008-03-06

  Provided are compounds which can be used in combination for treating diseases associated with a condition associated with cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which in combination can decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of the compounds.

  提供了一些化合物，可以组合使用来治疗与阿尔茨海默病淀粉样蛋白相关的疾病，如阿尔茨海默病。还提供了一种方法，通过给予治疗有效量的化合物组合来减少β-淀粉样蛋白的产生和细胞中的电容性钙离子进入，从而治疗或降低发生β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau异常过度磷酸化）和与阿尔茨海默病淀粉样蛋白相关的微胶质病变。此外，还提供了一种方法，通过给予诊断有效量的化合物来诊断动物或人类中与阿尔茨海默病淀粉样蛋白相关的疾病。
• Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
  申请人：Mullan J. Michael

  公开号：US20070037855A1

  公开（公告）日：2007-02-15

  Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.

  提供的化合物可用于治疗与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病，例如阿尔茨海默病。还提供了筛选此类化合物的方法，通过测量细胞中的电容性钙离子进入，其中细胞可以选择性地过度表达APP或其片段。还提供了通过给予治疗有效量的化合物来治疗或降低β-淀粉样蛋白产生、β-淀粉样蛋白沉积、β-淀粉样蛋白神经毒性（包括tau的异常高磷酸化）和与阿尔茨海默淀粉样蛋白在大脑中积累有关的微胶质细胞增生的方法。此外，还提供了通过给动物或人类施用诊断有效量的抑制电容性钙离子进入细胞的化合物来诊断与阿尔茨海默淀粉样蛋白在大脑中积累有关的疾病的方法。
• LIGAND-CONJUGATED MONOMERS
  申请人：MANOHARAN Muthiah

  公开号：US20090286973A1

  公开（公告）日：2009-11-19

  This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression.

  这项发明涉及用于抑制基因表达的化学修饰寡核苷酸制剂的组成和制备方法。